Correlation Between Bone Metabolic Markers and Bone Scan in Prostatic Cancer

Maéda, Hiroshi; Koizumi, Mitsuru; Yoshimura, Koji; Yamauchi, Tamio; Kawai, Tsuneo; Ogata, Etsuro

doi:10.1016/s0022-5347(01)65196-6

Cited by 78 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36 These markers can be used to guide decision making regarding the treatment of metastatic bone disease when the marker levels are elevated in patients with abnormal bone scans. [32][33][34] Whether the markers can be used to determine early bone involvement or micrometastases before the bone scan turns positive in high risk cancer patients still remains to be determined. [32][33][34] Whether the markers can be used to determine early bone involvement or micrometastases before the bone scan turns positive in high risk cancer patients still remains to be determined.…”

Section: Discussionmentioning

confidence: 99%

Biochemical markers and skeletal metastases

Demers

Costa

Lipton

2000

Cancer

166

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Biochemical markers and skeletal metastases

Demers

Costa

Lipton

2000

Cancer

166

View full text Add to dashboard Cite

“…The importance of the lytic component is obvious in that anti-resorption medicines, bisphosphonate and anti-RANKL monoclonal antibody, are used to treat skeletal metastases of prostate cancer [16, 17]. We formerly reported that both formation and resorption markers increased in prostate cancer patients with skeletal metastasis [18]. …”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups

et al. 2017

Self Cite

View full text Add to dashboard Cite

PurposeThe computer-assisted diagnostic system for bone scintigraphy (BS) BONENAVI is used to evaluate skeletal metastasis. We investigated its diagnostic performance in prostate cancer patients with and without skeletal metastasis and searched for the problems.MethodsAn artificial neural network (ANN) value was calculated in 226 prostate cancer patients (124 with skeletal metastasis and 101 without) using BS. Receiver operating characteristic curve analysis was performed and the sensitivity and specificity determined (cutoff ANN = 0.5). Patient’s situation at the time of diagnosis of skeletal metastasis, computed tomography (CT) type, extent of disease (EOD), and BS uptake grade were analyzed. False-negative and false-positive results were recorded.ResultsBONENAVI showed 82% (102/124) of sensitivity and 83% (84/101) specificity for metastasis detection. There were no significant differences among CT types, although low EOD and faint BS uptake were associated with low ANN values and low sensitivity. Patients showed lower sensitivity during the follow-up period than staging work-up. False-negative lesions were often located in the pelvis or adjacent to it. They comprised not only solitary, faint BS lesions but also overlaying to urinary excretion.ConclusionsBONENAVI with BS has good sensitivity and specificity for detecting prostate cancer’s osseous metastasis. Low EOD and faint BS uptake are associated with low sensitivity but not the CT type. Prostate cancer patients likely to have false-negative results during the follow-up period had a solitary lesion in the pelvis with faint BS uptake or lesions overlaying to urinary excretion.

show abstract

“…Markers of bone resorption, such as urine N-telopeptide (NTx) and bone-specific alkaline phosphatase, are higher in patients with bone metastasis compared to those without, indicative of elevated bone turnover despite the osteoblastic radiographic appearance[18, 19]. Increased osteoclast activity is independently associated with risk for subsequent skeletal complications, disease progression, and death[5, 20].…”

Section: Pathophysiology Of Bone Metastasis From Prostate Cancermentioning

confidence: 99%

Treatment and prevention of bone complications from prostate cancer

Lee¹,

Saylor²,

Smith³

2011

Bone

View full text Add to dashboard Cite

Bone metastases and skeletal complications are major causes of morbidity in prostate cancer patients. Despite the osteoblastic appearance of bone metastases on imaging studies, patients have elevated serum and urinary markers of bone resorption, indicative of high osteoclast activity. Increased osteoclast activity is independently associated with higher risk of subsequent skeletal complications, disease progression, and death. Osteoclast-targeted therapies are therefore a rational approach to reduction of risk for disease-related skeletal complications, bone metastases, and treatment-related fractures. This review focuses on recent advances in osteoclast-targeted therapy in prostate cancer. Bisphosphonates have been extensively studied in men with prostate cancer. Zoledronic acid significantly decreased the risk of skeletal complications in men with castration-resistant prostate cancer and bone metastases, and is FDA-approved for this indication. Denosumab is a human monoclonal antibody that binds and inactivates RANKL, a critical mediator of osteoclast differentiation, activation, and survival. Recent global phase 3 clinic trials demonstrated an emerging role for denosumab in the treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. Keywordsbisphosphonate; denosumab; metastasis; osteoclast; prostate cancer; RANKL; toremifene; zoledronic acid Clinical manifestations of bone complications in prostate cancerThe American Cancer Society estimates for 2009 included over 192,000 new cases of prostate cancer in the United States, accounting for 25% of cancer diagnoses in men, and over 27,000 deaths from metastatic disease [1]. The major site of hematogenous spread of prostate cancer is bone, seen in 80-90% of men with castration-resistant metastatic prostate cancer undergoing therapy [2,3], and 90% of patients at autopsy [4]. The most common sites of bone metastasis are the vertebral column, pelvis, ribs, long bones, and skull. These are

show abstract

Correlation Between Bone Metabolic Markers and Bone Scan in Prostatic Cancer

Abstract: Pyridinoline cross-linked carboxyterminal telopeptide might assist PSA and bone scintigraphy in monitoring metastatic bone activity of prostatic cancer.

Cited by 78 publications

References 15 publications

Biochemical markers and skeletal metastases

Biochemical markers and skeletal metastases

Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups

Treatment and prevention of bone complications from prostate cancer

Contact Info

Product

Resources

About